Jump to content

A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer (Q73350688)

From Wikidata

scientific article published on 01 January 1996

Language	Label	Description	Also known as
default for all languages	No label defined
English	A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer	scientific article published on 01 January 1996

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9157078%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9157078%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

phase II clinical trial

1 reference

based on heuristic

inferred from title

author name string

R S Witte

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9157078%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

P Hsieh

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9157078%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

P Elson

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9157078%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

M M Oken

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9157078%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

D L Trump

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9157078%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

publication date

1 January 1996

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9157078%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

language of work or name

0 references

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9157078%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9157078%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9157078%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

409-413

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9157078%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9157078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/9157078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Continuous infusion homoharringtonine (NSC 141633) in refractory acute nonlymphocytic leukemia. An ECOG pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/9157078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/9157078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of caracemide using bolus and infusion schedules

1 reference

https://pubmed.ncbi.nlm.nih.gov/9157078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The treatment of renal cell carcinoma with human leukocyte alpha-interferon

1 reference

https://pubmed.ncbi.nlm.nih.gov/9157078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Homoharringtonine is safe and effective for patients with acute myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/9157078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized prospective assessment of recombinant leukocyte A human interferon with or without aspirin in advanced renal adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/9157078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of vinblastine-CCNU, triazinate, and dactinomycin in advanced renal cell cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9157078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of vinblastine, methyl-CCNU, and medroxyprogesterone in advanced renal cell cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9157078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose lymphoblastoid interferon in advanced renal cell carcinoma: an Eastern Cooperative Oncology Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/9157078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of PALA and AMSA in advanced renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/9157078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/9157078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II studies of PCNU and bisantrene in advanced renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/9157078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/9157078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/9157078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of caracemide (NSC 253272) in advanced unresectable non-small cell bronchogenic carcinoma. An Illinois Cancer Council study

1 reference

https://pubmed.ncbi.nlm.nih.gov/9157078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/9157078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of homoharringtonine in patients with recurrent primary malignant central nervous system tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/9157078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/9157078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: a phase II Illinois Cancer Council Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/9157078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/9157078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of interferon alfa-2a, recombinant (Roferon-A) in metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/9157078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of single-agent therapy with megestrol acetate, VP-16-213, cyclophosphamide, and dianhydrogalactitol in advanced renal cell cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9157078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/9157078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hormonal therapy and chemotherapy of renal-cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/9157078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of caracemide in advanced or recurrent non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9157078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q73350688&oldid=2407874468"